Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Licensure Safety Study of ISENTRESS in a US Managed Care Network

Next Previous
Trial Profile

Post-Licensure Safety Study of ISENTRESS in a US Managed Care Network

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 27 Oct 2018 Results published in the HIV Clinical Trials
  • 06 Apr 2016 Number of groups changed from 3 to 7 in treatment table, Time frame for primary endpoint changed (January 2000 - December 2014 to Historical Cohort: up to 33 months (January 2005 to October 2007); Raltegravir and Concurrent Cohorts: up to 69 months (October 2007 to June 2013))
  • 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top